In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey

被引：7

作者：

Olbrecht, Margo ^{[1
]}

Echahidi, Fedoua ^{[1
]}

Pierard, Denis ^{[1
]}

Peeters, Charlotte ^{[3
]}

Vandamme, Peter ^{[3
]}

Wybo, Ingrid ^{[1
]}

Demuyser, Thomas ^{[1
,2
]}

机构：

[1] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Natl Reference Ctr Burkholderia Cepacia Complex &, Dept Microbiol & Infect Control, Brussels, Belgium

[2] Vrije Univ Brussel VUB, Fac Med & Pharm, Ctr Neurosci, AIMS Lab, Brussels, Belgium

[3] Univ Ghent, Fac Sci, Dept Biochem & Microbiol, Lab Microbiol, Ghent, Belgium

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 07期

关键词：

Achromobacter; in vitro susceptibility; antibiotic resistance; cystic fibrosis; XYLOSOXIDANS; RESISTANCE; PREVALENCE; AVIBACTAM;

D O I：

10.1128/aac.00379-23

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.

引用

收藏

页数：6

相关论文

共 38 条

[1] Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates [J].

Amoureux, Lucie ;

Bador, Julien ;

Zouak, Fatma Bounoua ;

Chapuis, Angelique ;

de Curraize, Claire ;

Neuwirth, Catherine .

JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (04) :486-494

[2] Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: First French data [J].

Amoureux, Lucie ;

Bador, Julien ;

Siebor, Eliane ;

Taillefumier, Nathalie ;

Fanton, Annlyse ;

Neuwirth, Catherine .

JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (02) :170-176

[3] Innate Aminoglycoside Resistance of Achromobacter xylosoxidans Is Due to AxyXY-OprZ, an RND-Type Multidrug Efflux Pump [J].

Bador, Julien ;

Amoureux, Lucie ;

Blanc, Emmanuel ;

Neuwirth, Catherine .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (01) :603-605

[4] First Description of an RND-Type Multidrug Efflux Pump in Achromobacter xylosoxidans, AxyABM [J].

Bador, Julien ;

Amoureux, Lucie ;

Duez, Jean-Marie ;

Drabowicz, Anthony ;

Siebor, Eliane ;

Llanes, Catherine ;

Neuwirth, Catherine .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (10) :4912-4914

[5] Molecular Characterization of Achromobacter Isolates from Cystic Fibrosis and Non-Cystic Fibrosis Patients in Madrid, Spain [J].

Barrado, Laura ;

Branas, Patricia ;

Angeles Orellana, M. ;

Teresa Martinez, M. ;

Garica, Gloria ;

Otero, Joaquin R. ;

Chaves, Fernando .

JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (06) :1927-1930

[6] In Vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens [J].

Caverly, Lindsay J. ;

Spilker, Theodore ;

Kalikin, Linda M. ;

Stillwell, Terri ;

Young, Carol ;

Huang, David B. ;

LiPuma, John J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (01)

[7]

CLSI, 2022, CLSI supplement M100

[8] Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK [J].

Coward, Amy ;

Kenna, Dervla T. D. ;

Perry, Claire ;

Martin, Kate ;

Doumith, Michel ;

Turton, Jane F. .

JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (04) :479-485

[9] Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases [J].

Ehmann, David E. ;

Jahic, Haris ;

Ross, Philip L. ;

Gu, Rong-Fang ;

Hu, Jun ;

Durand-Reville, Thomas F. ;

Lahiri, Sushmita ;

Thresher, Jason ;

Livchak, Stephania ;

Gao, Ning ;

Palmer, Tiffany ;

Walkup, Grant K. ;

Fisher, Stewart L. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (39) :27960-27971

[10] What is the role of Achromobacter species in patients with cystic fibrosis? [J].

Esposito, Susanna ;

Pisi, Giovanna ;

Fainardi, Valentina ;

Principi, Nicola .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2021, 26 (12) :1613-1620

← 1 2 3 4 →